US Agency for International Development, Washington, DC, USA.
RTI International, Washington, DC, USA.
Clin Infect Dis. 2020 Feb 14;70(5):958-964. doi: 10.1093/cid/ciz742.
In 2006, following direct advocacy and published rationale, the US Agency for International Development (USAID) established a neglected tropical diseases (NTDs) program to support the scale-up of integrated platforms to target the elimination and control of 5 NTDs-lymphatic filariasis, trachoma, onchocerciasis, schistosomiasis, and soil-transmitted helminthiasis. By 2017, more than 2.3 billion NTD treatments had been delivered to at-risk populations in 25 countries, leveraging $19 billion in donated drugs-approximately $26 dollars in donated medicine per $1 spent by USAID. As a result, most of the supported countries are on track to achieve their elimination goals (for lymphatic filariasis and trachoma) by 2020 or 2021 and their control goals soon thereafter. Though "small" when compared to other global health initiatives, this investment proved to be catalytic, and indeed highlights how foreign assistance funding can be transformative, in reducing the burden of major global health conditions such as NTDs.
2006 年,在美国国际开发署(USAID)的积极倡导和公开论证下,该机构成立了一个被忽视的热带病(NTD)项目,以支持扩大综合平台,消除和控制 5 种被忽视的热带病——淋巴丝虫病、沙眼、盘尾丝虫病、血吸虫病和土源性线虫病。截至 2017 年,在 25 个国家,已有超过 23 亿次的 NTD 治疗惠及高危人群,利用了 190 亿美元的捐赠药品——美国国际开发署每支出 1 美元,就有大约 26 美元的捐赠药品。因此,大多数受援国有望在 2020 年或 2021 年实现消除(淋巴丝虫病和沙眼)目标,并在随后不久实现控制目标。虽然与其他全球卫生倡议相比,这一投资规模较小,但事实证明它具有催化作用,确实凸显了外国援助资金如何能够改变局面,减少被忽视的热带病等主要全球卫生状况的负担。